Stuart T. Weisbrod, Ph.D.
Founder, Chief Investment Officer
Buy-side Experience: Dr. Weisbrod was the founder of the Merlin BioMed Group, a broad-based healthcare investment firm, and served as its Chief Investment Officer from January 1998 until it closed in December 2007. The funds managed by Dr. Weisbrod at Merlin BioMed returned a compounded annualized return of over 20%. He began his buy-side career at Harpel Advisors in 1994 as a Partner, responsible for the firm’s healthcare and cyclical investment activities. He joined Oracle Partners in January 1995 as a Partner, focusing on the biotechnology and pharmaceutical sectors of healthcare.
Sell-side Experience: Dr. Weisbrod began his investment career as a securities analyst at Prudential-Bache in 1986 and subsequently joined Merrill Lynch as a First Vice President in 1990. From 1987-1993 he consistently ranked in the top three in both the Institutional Investor and Greenwich Associates rankings of biotechnology analysts in the U.S.
Academic Training: Dr. Weisbrod received a Ph.D. in biochemistry from Princeton University in 1980 and an MBA in finance from Columbia University in 1986. From 1980-1984 he held research fellowships at the Medical Research Council Lab in Cambridge, England and at the Cold Spring Harbor Laboratory in New York. Dr. Weisbrod currently serves on the Dean’s Council of the Princeton University Graduate School.